Natera, Inc. (NTRA): John Steuart , director of Natera, Inc. purchased 83,752 shares on Jun 19, 2016. The Insider buying transaction was reported by the company on Jun 21, 2016 to the Securities and Exchange Commission. The shares were purchased at $11.94 per share for a total value of $999,998.88 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 3, 2016, Herm Rosenman (Chief Financial Officer) sold 1,806 shares at $12.04 per share price.On Feb 3, 2016, Jonathan Sheena (Chief Technology Officer) sold 10,000 shares at $8.03 per share price.Also, On Jan 5, 2016, Matthew Rabinowitz (CEO, President) sold 54,683 shares at $10.22 per share price.On Jul 9, 2015, James Healy (director) purchased 350,000 shares at $18.00 per share price.
Natera Inc: On Monday, Jun 20, 2016 heightened volatility was witnessed in Natera Inc which led to swings in the share price. The shares opened for trading at $11.65 and hit $11.8605 on the upside , eventually ending the session at $11.6, with a gain of 1.22% or 0.14 points. The heightened volatility saw the trading volume jump to 1,88,132 shares. The 52-week high of the share price is $24.36 and the company has a market cap of $595 M . The 52-week low of the share price is at $6.52.
Company has been under the radar of several Street Analysts.Natera Inc is Reiterated by The Benchmark Company to Buy and the brokerage firm has raised the Price Target to $ 16 from a previous price target of $15 .The Rating was issued on May 23, 2016.Natera Inc is Reiterated by The Benchmark Company to Buy and the brokerage firm has raised the Price Target to $ 15 from a previous price target of $14 .The Rating was issued on May 11, 2016.Natera Inc is Initiated by The Benchmark Company to Buy and the brokerage firm has set the Price Target at $14. The Rating was issued on Apr 19, 2016.
Natera Inc. is a diagnostics company. The Company has molecular and bioinformatics technology that it deploys to change genetic diseases across the world. Its molecular assays measure various regions across the genome from samples as small as a single cell. Its statistical algorithms combine these measurements with the available data to detect a range of serious conditions. It is engaged in developing products for various oncology applications. In addition to its direct sales force in the United States the Company has a global network of over 70 laboratory and distribution partners. It has introduced a cloud-based distribution model. It also has launched seven molecular diagnostic tests. The Company launched Panorama which is its non-invasive prenatal test (NIPT). Its products include Pre-implantation Genetic Screening Pre-implantation Genetic Diagnosis Products of Conception Non-Invasive Paternity Testing High Throughput Carrier Screening and Non-Invasive Prenatal Testing.